Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 5:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Parkinsons Clear all
Recruiting No phase listed Observational

Deep Brain Stimulation for Visuomotor Function in Parkinson's Disease

NCT05400499
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 2 Interventional

A Study of NE3107 in Early Parkinson's

NCT06757010
View directory record Official record
Conditions
Parkinsons Disease (PD)
Interventions
NE3107, Placebo
Drug
Lead sponsor
BioVie Inc.
Industry
Eligibility
45 Years to 80 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Farmington Hills, Michigan • Amherst, New York • Morrisville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cognitive Dysfunction In Parkinson's

NCT02468804
View directory record Official record
Conditions
Parkinson's
Interventions
rTMS, Sham TMS
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
45 Years to 90 Years
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Sep 23, 2026, 5:02 PM EDT
Recruiting Not applicable Interventional

Transcranial Direct Current Stimulation for Motor Function and Fatigue in PD

NCT06883266
View directory record Official record
Conditions
Parkinsons Disease (PD)
Interventions
transcranial direct current stimulation (tDCS), Sham (No Treatment)
Device
Lead sponsor
Sanford Health
Other
Eligibility
Not listed
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 2 Interventional Results available

Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease

NCT02954978
View directory record Official record
Conditions
Parkinson Disease, Parkinsons Disease With Dementia
Interventions
Placebo Oral Capsule, Nilotinib 150mg oral capsule [Tasigna], Nilotinib 300mg oral capsule [Tasigna]
Drug
Lead sponsor
Georgetown University
Other
Eligibility
40 Years to 90 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 23, 2026, 5:02 PM EDT
Not listed Phase 2 Interventional

A Study of Efficacy and Safety of Eltoprazine HCl for Treating Levodopa-induced Dyskinesia in Parkinson's Disease Patients

NCT02439125
View directory record Official record
Conditions
Parkinson's Disease, Dyskinesia
Interventions
Eltoprazine HCl, Placebo
Drug
Lead sponsor
Amarantus BioScience Holdings, Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2016 · Synced Sep 23, 2026, 5:02 PM EDT
Withdrawn No phase listed Observational

Biomarkers in Neurodegenerative Diseases

NCT04055532
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Alzheimer Disease (AD), Dementia With Lewy Bodies (DLB), Frontotemporal Lobar Degeneration (FTLD), Parkinsons Disease With Dementia (PDD), Transient Epileptic Amnesia (TEA), Temporal Lobe Epilepsy (TLE), Spinocerebellar Ataxias (SCA), HIV Associated Neurocognitive Disorder (HAND), Amyotrophic Lateral Sclerosis (ALS), Primary Lateral Sclerosis (PLS)
Interventions
Neuraceq
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Timeline
2019 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 11, 2019 · Synced Sep 23, 2026, 5:02 PM EDT
Completed No phase listed Observational

Dance Exercise as Novel Complementary Therapy for Parkinson's Disease

NCT01163344
View directory record Official record
Conditions
Parkinsons Disease
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
40 Years to 79 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Sep 23, 2026, 5:02 PM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

NCT06944522
View directory record Official record
Conditions
Parkinsons Disease (PD)
Interventions
bemdaneprocel, Sham surgery
Biological · Procedure
Lead sponsor
BlueRock Therapeutics
Industry
Eligibility
45 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
34
States / cities
Scottsdale, Arizona • Sun City, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic Study of LY03003 in Patients With Parkinson's Disease

NCT03589066
View directory record Official record
Conditions
Parkinson Disease
Interventions
LY03003
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Hallandale, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Not applicable Interventional

The Effects of Nicotine Chewing Gum in Parkinson's Disease

NCT02452125
View directory record Official record
Conditions
Low Blood Pressure, Parkinsons Disease
Interventions
Nicotine gum
Dietary Supplement
Lead sponsor
New York Institute of Technology
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Old Westbury, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Sep 23, 2026, 5:02 PM EDT
Not yet recruiting Not applicable Interventional

Gamification and Physical Activity in PD

NCT07286994
View directory record Official record
Conditions
Parkinson Disease
Interventions
Gamification, Feedback control
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 89 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 23, 2026, 5:02 PM EDT
Not yet recruiting Phase 2 Interventional

Prescriptive Infusion Algorithm (PIA)

NCT07215403
View directory record Official record
Conditions
PARKINSON DISEASE (Disorder)
Interventions
Prescriptive Infusion Algorithm, AB-1005
Procedure · Drug
Lead sponsor
AskBio Inc
Industry
Eligibility
45 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Cleveland, Ohio • Columbus, Ohio • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 23, 2026, 5:02 PM EDT
Recruiting Phase 2 Interventional

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

NCT06680830
View directory record Official record
Conditions
Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic
Interventions
NEU-411, Placebo
Drug · Other
Lead sponsor
Neuron23 Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
45
States / cities
Sun City, Arizona • Little Rock, Arkansas • Fresno, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease

NCT02055274
View directory record Official record
Conditions
Parkinson's Disease
Interventions
LY03003, Neupro
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Long Beach, California • Orlando, Florida • Douglasville, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Sep 23, 2026, 5:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Battery-preserving Stimulation Patterns for Deep Brain Stimulation

NCT02569021
View directory record Official record
Conditions
Parkinsons Disease, Essential Tremor
Interventions
Biphasic DBS stimulation, Unified Parkinson's Disease Rating Scale, Tremor Rating Scale, Kinesia accelerometer, Trigno wireless system, GaitRite walking assessment.
Device · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 23, 2016 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of AMDX-2011P as a Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy

NCT05542576
View directory record Official record
Conditions
Parkinson Disease, Amyotrophic Lateral Sclerosis
Interventions
AMDX2011P
Drug
Lead sponsor
Amydis Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Newport Beach, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients

NCT00479401
View directory record Official record
Conditions
Early Parkinson Disease (Early PD)
Interventions
Pramipexol Extended Release, Pramipexol Immediate Release, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
30 Years and older
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
16
States / cities
Gilbert, Arizona • Sun City, Arizona • La Jolla, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Sep 23, 2026, 5:02 PM EDT
Recruiting Not applicable Interventional

Neurologic Stem Cell Treatment Study

NCT02795052
View directory record Official record
Conditions
Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders, Stroke, Traumatic Brain Injury, Cadasil, Chronic Traumatic Encephalopathy, Cerebral Infarction, Cerebral Ischemia, Cerebral Stroke, Cerebral Hemorrhage, Parkinson, Multi-System Degeneration, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, ALS, Amyotrophic Lateral Sclerosis, Neuropathy, Diabetic Neuropathies, Alzheimer Disease, Dementia, Frontotemporal Dementia, Lewy Body Disease, Cognitive Impairment, Lewy Body Variant of Alzheimer Disease
Interventions
Intravenous and Intranasal BMSC
Procedure
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
2
States / cities
Westport, Connecticut • Coral Springs, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Not applicable Interventional

Exercise Dosing Trial for Individuals With Parkinson's Disease

NCT02676804
View directory record Official record
Conditions
Parkinsons Disease
Interventions
High-intensity, aerobic exercise.
Other
Lead sponsor
University of Virginia
Other
Eligibility
45 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 1Phase 2 Interventional

Chinese Exercise Modalities in Parkinson's Disease

NCT00029809
View directory record Official record
Conditions
Parkinson Disease
Interventions
Chinese exercise modalities
Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
40 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 17, 2006 · Synced Sep 23, 2026, 5:02 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease

NCT04777331
View directory record Official record
Conditions
Parkinsons Disease
Interventions
Prasinezumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 85 Years
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fullerton, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Rural Dementia Caregiver Project

NCT04428112
View directory record Official record
Conditions
Depression, Stress, Psychological, Self Efficacy, Loneliness, Social Isolation, Health Care Utilization, Dementia, Dementia Alzheimers, Dementia of Alzheimer Type, Dementia, Vascular, Dementia Frontal, Dementia, Lewy Body, Dementia, Mixed, Dementia in Parkinsons Disease, Dementia, HIV, Dementia Frontotemporal, Dementia, Multi-Infarct
Interventions
Building Better Caregivers Workshop, Attention Control
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Sep 23, 2026, 5:02 PM EDT
Recruiting Phase 1 Interventional

Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.

NCT07064005
View directory record Official record
Conditions
Parkinsons Disease (PD)
Interventions
Gamma- glutamylcysteine
Drug
Lead sponsor
Pravat Mandal
Other
Eligibility
50 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 23, 2026, 5:02 PM EDT